Medical OncologyFasterScanNCT05385718

Ezra Faster Scan Study

An observational study of Medical Oncology and Cancer, run by Ezra AI, Inc. at 5 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Trial summary

The Ezra Faster Scan study uses non-invasive magnetic resonance imaging (MRI) technology that can "visually" detect early and late-stage cancer, and other pathologies. MRIs use a magnetic field and radio waves to create a 3-dimensional (3D) image of an individual's body without using ionizing radiation. Read more about this study

Who is it for?: Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for: Medical Oncology, Cancer, Healthy
What is being tested?: Magnetic Resonance Imaging
How many people: 694 participants
Where: 5 sitesUnited States
Study dates: 1 Jun 2022to 24 Feb 2025
Phase: Observational
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
Healthy volunteers accepted
Adult, Older adult

Study population: Participants may be from the general public and located or able to travel to MRI facilities located in New York, New York; Queens, New York; Brooklyn, New York; Great Neck, New York; Irvine, California; Sunnyvale, California; Walnut Creek, California; San Francisco, California; Miami, Florida; Aventura, Florida. Participants may also be those who have accessed Ezra commercial MRI services in the past, or have scheduled commercial MRI services pending.

Who may be able to join

Ability to provide legal informed consent and 18 years of age or older
Resident of the contiguous United States and located within proximity of a designated research MRI facility
Ability to travel to designated research MRI facilities

Who cannot join

Unable to receive an MRI due to existing implanted medical devices that may be disrupted by magnetic field or metal components/fragments that may migrate due to magnetic fields (pacemaker or defibrillator, stimulators, or stimulator wires (pacing leads), non-removeable metal dentures/braces/wires, surgical clips, (drug) pumps. Note metallic dental crowns or fillings are permitted.
Those with orbital (eye socket) trauma caused by a metallic object
Those with metallic fragments within the eye (foundry workers)
Those with implanted cardiac pacemakers, implantable cardioverter defibrillators (ICDs), or diaphragmatic pacemakers, cardiac resynchronization therapy devices, implantable cardiovascular monitors, implantable loop recorders, neurostimulators
Those with intra-cranial vascular clips (aneurysm), or prosthetic heart valve
Those with shrapnel form a prior accident

Show all 24Show fewer

Those with a LINX Reflux Management System to control gastro esophageal reflux disease (GERD)
Those with non-removable insulin pumps or other drug pumps
Those with cochlear implants
Those with breast (inflatable breast tissue implants) or other tissue expanders (cosmetic or other implant)
Those with tubal ligation clips or non-removable intrauterine device (IUD)
Those with Sensimed Triggerfish ocular monitoring systems (glaucoma)
Those receiving ambulatory care
Employee of Ezra Health of California, P.C., Ezra AI Incorporated or Ezra AI Canada Incorporated
Mental health disability, cognitive disability, neurological or other existing condition that may impact ability to provide informed consent
Those that recently experienced a stroke that may impair judgement
Those that have some difficulty or higher, remembering, concentrating, communicating, or being understood (sponsor reviewed)
Individuals who otherwise may require a legally authorized individual (LAR) to provide consent on their behalf
Those who do not have access to the internet through a mobile device or computer
Those who are pregnant at the time of informed consent or prior to a scheduled MRI appointment
Those who are incarcerated or on probation
Those who may not have reading proficiency of study supported document languages (questionnaires, consent forms, or third-party oral translation services)
Those who cannot read due to visual impairment and cannot provide an impartial witness to support informed consent or study survey questionnaires
Those with a hearing impairment and cannot provide an impartial witness to support informed consent

Trial locations and contacts

5 sites in 1 country.

City, postcode or hospital

5 sites in 1 country

United States5 sites

Various Locations
Beverly Hills, California, 90211
Various Locations
Chino Hills, California, 91709
Various Locations
Irvine, California, 92604
Various Locations
Los Gatos, California, 95032
Various Locations
New York, New York, 10075

Other trials in United States

About this study

The purpose of this research is to decrease the amount of time required by an individual to complete an early cancer screening comprehensive magnetic resonance imaging (MRI) scan, such as the Ezra Full Body MRI imaging scan. If the time required to conduct a comprehensive scan is reduced, the cost of the scan may also decrease. By decreasing consumer costs and time, more individuals may be able to afford MRI-based early cancer screening technology.

Participants in this study will undergo a minimum 30-minute MRI session. These sessions will be used to evaluate new MRI "instructions" that allow for a faster MRI scan time. The images will also be used to develop mathematical models or machine learning tools that allow images to be enhanced. By enhancing images using machine learning, they may be restored to a quality typically observed in MRI sessions with longer scan (acquisition) times.

To read more about the study, potential participants may review the informed consent form located below in the References section. Potential participants may email research.fasterscan@ezra.com, or call 516.340.1221.

See study Eligibility Criteria below.

Conditions: Medical Oncology, Cancer, Healthy
Being tested: Magnetic Resonance Imaging
Keywords: Magnetic Resonance Imaging, Early Cancer Detection, Machine Learning
Medical subject headings: Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Magnetic Resonance ImagingOther
Also called MRI
Participants are required to undergo a non-invasive magnetic resonance imaging (MRI) scan approximately 30 minutes in length.

Study groups in NCT05385718
Study group	Role	What they receive
Observational		The observational group may include those 18 years and older, with retrospective MRI data, or those whom prospective MRI images are collected as a participant. This study is decentralized, non-therapeutic and non-interventional. Receives: Other: Magnetic Resonance Imaging

What is being measured

The primary outcome is the main question the study is designed to answer.

Accelerated MRI Sequence Protocol Time (s)
The MRI scan time (minutes, seconds) for MRI instructions or sequences to be completed and qualitative feedback from MRI technologists and radiologists on execution of instrument instructions.
Measured: Approximately 30 minutes for each participant scan . Additional computational analysis of images throughout the study duration.
Statistical Analysis of MRI Images (Accelerated)
Computed image signal-to-noise and contrast-to-noise ratios of machine learning-restored accelerated images relative to accelerated images.
Measured: Approximately 30 minutes for each participant scan. Additional computational analysis of images throughout the study duration.
Statistical Analysis of MRI Images (Reference)
Computed image signal-to-noise and contrast-to-noise ratios of machine learning-restored accelerated images relative to reference images.
Measured: Approximately 30 minutes for each participant scan. Additional computational analysis of images throughout the study duration.
Statistical Analysis of MRI Images (Likert)
Visual radiologist review of reference and machine learning restored images. Images are reviewed using a Likert scale, comparing a reference image to a machine learning restored image. The scale grades are a radiologist's objective opinion of whether a machine learning restored image is similar to a reference image. If the machine learning image is worse, the radiologist rates the image strongly disagree or -2, if the machine learning image is better than the reference image, the radiologist selects strongly agree or 2. The Likert scale extends from worse to improved in the following order; strongly disagree (worse) -2, disagree -1, neither agree or disagree (neutral) 0, agree 1, or strongly agree 2. The minimum value is -2 and the maximum value is 2. A higher score greater than 0 indicates a better image, a lower score less than 0 indicates a worse image or outcome.
Measured: Approximately 10 minutes of a radiologist's time. Additional analysis of images throughout the study duration.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1 Jun 202224 Feb 2025

First posted23 May 2022
Study start1 Jun 2022
Primary completion24 Feb 2025
Study completion24 Feb 2025

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Medical OncologyStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Observational
Observational model: Other
Time perspective: Other
Enrolment: 694 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05385718
Sponsor's protocol ID: Ezra_002
Acronym: FasterScan
Status last verified: Sep 2024
First submitted: 17 May 2022
Last updated: 3 Mar 2025
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No: Deidentified data may be shared for the purpose of research. Algorithms based on research may be commercialized or published.

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingObservational study
Connect for Cancer Prevention Study (Connect)
Cancer, General Research Use
Not yet recruitingObservational study
A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region
Chronic Myeloid Leukemia
Recruiting
Medical Payment Case Management for Financial Toxicity in Patients With Primary Bone Tumors: A Randomized Controlled Trial
Bone Tumor, Bone Cancer
RecruitingObservational study
A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer
Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Low-volume Metastasis
RecruitingObservational study
Preoperative Magnetic Tracking in Breast Surgery in France: French Medical-economic Study.
Breast Cancer, Medico-economic Impact

All Medical Oncology trials

Study at a glance

From the registry record, last updated by the sponsor on 3 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Ezra Faster Scan Study
ClinicalTrials.gov ID: NCT05385718
Acronym / sponsor ID: FasterScan / Ezra_002
Conditions: Medical Oncology, Cancer, Healthy
Keywords: Magnetic Resonance Imaging, Early Cancer Detection, Machine Learning
Study type: Observational
Recruitment status: Completed
Enrolment: 694 participants (actual)
Lead sponsor: Ezra AI, Inc.Industry (pharma, biotech, devices)
Study start: 1 Jun 2022 (actual)
Primary completion: 24 Feb 2025 (actual)
Study completion: 24 Feb 2025 (actual)
First posted: 23 May 2022 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

See study Eligibility Criteria below.

Study design

Observational model: Other
Time perspective: Other
Number of arms: 1

Arm	Type	Receives
Observational	–	Other: Magnetic Resonance ImagingThe observational group may include those 18 years and older, with retrospective MRI data, or those whom prospective MRI images are collected as a participant. This study is decentralized, non-therapeutic and non-interventional.

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Accepted
Age groups: Adult, Older adult
Study population: Participants may be from the general public and located or able to travel to MRI facilities located in New York, New York; Queens, New York; Brooklyn, New York; Great Neck, New York; Irvine, California; Sunnyvale, California; Walnut Creek, California; San Francisco, California; Miami, Florida; Aventura, Florida. Participants may also be those who have accessed Ezra commercial MRI services in the past, or have scheduled commercial MRI services pending.

Key inclusion criteria (3 listed)

Ability to provide legal informed consent and 18 years of age or older
Resident of the contiguous United States and located within proximity of a designated research MRI facility
Ability to travel to designated research MRI facilities

Key exclusion criteria (24 listed)

Unable to receive an MRI due to existing implanted medical devices that may be disrupted by magnetic field or metal components/fragments that may migrate due to magnetic fields (pacemaker or defibrillator, stimulators, or stimulator wires (pacing leads), non-removeable metal dentures/braces/wires, surgical clips, (drug) pumps. Note metallic dental crowns or fillings are permitted.
Those with orbital (eye socket) trauma caused by a metallic object
Those with metallic fragments within the eye (foundry workers)
Those with implanted cardiac pacemakers, implantable cardioverter defibrillators (ICDs), or diaphragmatic pacemakers, cardiac resynchronization therapy devices, implantable cardiovascular monitors, implantable loop recorders, neurostimulators
Those with intra-cranial vascular clips (aneurysm), or prosthetic heart valve

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Magnetic Resonance ImagingAlso: MRIParticipants are required to undergo a non-invasive magnetic resonance imaging (MRI) scan approximately 30 minutes in length.	Other	Observational

Primary outcome

Accelerated MRI Sequence Protocol Time (s)
Time frame: Approximately 30 minutes for each participant scan . Additional computational analysis of images throughout the study duration.
The MRI scan time (minutes, seconds) for MRI instructions or sequences to be completed and qualitative feedback from MRI technologists and radiologists on execution of instrument instructions.
Statistical Analysis of MRI Images (Accelerated)
Time frame: Approximately 30 minutes for each participant scan. Additional computational analysis of images throughout the study duration.
Computed image signal-to-noise and contrast-to-noise ratios of machine learning-restored accelerated images relative to accelerated images.
Statistical Analysis of MRI Images (Reference)
Time frame: Approximately 30 minutes for each participant scan. Additional computational analysis of images throughout the study duration.
Computed image signal-to-noise and contrast-to-noise ratios of machine learning-restored accelerated images relative to reference images.
Statistical Analysis of MRI Images (Likert)
Time frame: Approximately 10 minutes of a radiologist's time. Additional analysis of images throughout the study duration.
Visual radiologist review of reference and machine learning restored images. Images are reviewed using a Likert scale, comparing a reference image to a machine learning restored image. The scale grades are a radiologist's objective opinion of whether a machine learning restored image is similar to a reference image. If the machine learning image is worse, the radiologist rates the image strongly disagree or -2, if the machine learning image is better than the reference image, the radiologist selects strongly agree or 2. The Likert scale extends from worse to improved in the following order; strongly disagree (worse) -2, disagree -1, neither agree or disagree (neutral) 0, agree 1, or strongly agree 2. The minimum value is -2 and the maximum value is 2. A higher score greater than 0 indicates a better image, a lower score less than 0 indicates a worse image or outcome.

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 3 Mar 2025.
Individual participant dataSharing planned: No. Deidentified data may be shared for the purpose of research. Algorithms based on research may be commercialized or published.

Related trials for Medical Oncology

RecruitingObservational study
Connect for Cancer Prevention Study (Connect)
Cancer, General Research Use
Not yet recruitingObservational study
A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region
Chronic Myeloid Leukemia
Recruiting
Medical Payment Case Management for Financial Toxicity in Patients With Primary Bone Tumors: A Randomized Controlled Trial
Bone Tumor, Bone Cancer
RecruitingObservational study
A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer
Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Low-volume Metastasis
RecruitingObservational study
Preoperative Magnetic Tracking in Breast Surgery in France: French Medical-economic Study.
Breast Cancer, Medico-economic Impact

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

David Girard principal investigator

Ezra AI, Inc.

5 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

An observational study of Medical Oncology and Cancer, run by Ezra AI, Inc. at 5 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Accelerated MRI Sequence Protocol Time (s) (time frame: Approximately 30 minutes for each participant scan . Additional computational analysis of images throughout the study duration.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05385718.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2025.